In the framework of the Second National Congress of Researchers of the Spondyloarthritis Group of the Spanish Society of Rheumatology (GRESSER), held in Madrid, experts discussed how early detection, precision medicine and better control of pain are the main challenges in the field of medicine.
Axial spondyloarthritis and psoriatic arthritis.
According to Raquel Almodovar, a rheumatologist at the Alcorcón University Hospital in Madrid, the field of axial spondyloarthritis and psoriatic arthritis has seen significant developments in recent years. “It should be highlighted Genetic studies that shed light on the genetic basis Axial spondyloarthritis and psoriatic arthritis, and identifying some genetic markers associated with an increased risk of developing these diseases. “This could open new horizons for understanding genetic predisposition and developing more specific therapeutic approaches.” It has also been developed New treatments with different mechanisms of action Which has provided more specific and effective options for many patients. Likewise, the importance of collaboration between rheumatologists and other relevant professionals has been recognised. This has been key to addressing not only inflammation, but also aspects such as skin, gut, eye, cardiovascular risk, mental health, and patients' overall quality of life.
Improvements in axial spondyloarthritis and psoriatic arthritis
Likewise, Almodóvar mentioned advances in imaging techniques, such as ultrasound, MRI, and CT, by providing better assessment of the inflammatory activity and structural damage of the disease, allowing for earlier diagnosis, as well as improved therapeutic decisions. In his opinion, “the other crucial challenge relates to A Greater control of pain and inflammation associated with spondyloarthritis. Although treatment options exist, individual response to treatments can vary greatly. Therefore, continued research is needed to develop more effective and personalized treatments that specifically address the pathogenic mechanisms of these diseases. It is worth remembering that toSpondyloarthritis is a group of rheumatic diseases that includes diseases such as axial spondyloarthritis or formerly known as ankylosing spondylitis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, or reactive arthritis. Estimates indicate that its prevalence may exceed 1.2 percent of the population, which equates to about half a million people affected in Spain.
